Trial Profile
A multi-center, open-label, single-arm, Phase 3b study of macitentan in patients with pulmonary arterial hypertension to psychometrically validate the French, Italian and Spanish versions of the PAH-SYMPACT
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Aug 2019
Price :
$35
*
At a glance
- Drugs Macitentan (Primary)
- Indications Pulmonary arterial hypertension
- Focus Registrational; Therapeutic Use
- Acronyms ORCHESTRA
- Sponsors Actelion Pharmaceuticals
- 17 Oct 2015 Status changed from recruiting to completed as reported by European Clinical Trials Database.
- 07 Apr 2014 New trial record